Pharmacoeconomic analysis of therapies for pediatric patients

References

• Alemayehu B, Warner KE. The lifetime distribution of healthcare costs. Health Serv. Res. 39,627–642 (2004).
   PubMed Web of Science ®Google Scholar
• Ackerman TF. The ethics of drug research in children. Paediatr. Drugs 3,29–41 (2001).
   PubMedGoogle Scholar
• Holdsworth MT. Pediatric drug research — the road less traveled. Ann. Pharmacother. 37,586–591 (2003).
   PubMedGoogle Scholar
• Conroy S, McIntyre J, Choonara I, Stephenson T. Drug trials in children: problems and the way forward. Br. J. Clin. Pharmacol. 49,93–97 (2000).
   PubMed Web of Science ®Google Scholar
• Robertson WO. Chemicals, children and research dollars. Vet. Hum. Toxic& 40, 308–309 (1998).
   PubMedGoogle Scholar
• Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J Med. 62,200-208 (1977).
   Google Scholar
• Agarwala S, Kumar R, Bhatnagar V, Bajpai M, Gupta DK, Mitra DK. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J. Pediatr. Surg. 35, 1786–1789 (2000).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, Perez- Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl. J. Med. 324,808–815 (1991).
   Google Scholar
• Seifert CE Nesser ME, Thompson DE Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann. Pharmacother. 28,1063–1072 (1994).
   Google Scholar
• Wexler LH, Andrich MP, Venzon D et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. j Clin. arca 14,362–372 (1996).
   Google Scholar
• Wexler LH. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Semin. Oncol. 25,86–92 (1998).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl. J. Med. 351,145–153 (2004).
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266,1672–1677 (1991).
   Google Scholar
• Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin. Oncol. 21,21–28 (1994).
   PubMed Web of Science ®Google Scholar
• Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. I Pain Symptom Manage. 25,512–518 (2003).
   PubMed Web of Science ®Google Scholar
• Case DC Jr, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J. Natl Cancer Inst. 85,801–806 (1993).
   PubMedGoogle Scholar
• Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 18,156–169 (1998).
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin a in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times weekly dosing. J Clin. Oncol. 19,2875–2882 (2001).
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin. Oncol. 20,4083–4107 (2002).
   PubMed Web of Science ®Google Scholar
• Feusner J, Hastings C. Recombinant human erythropoietin in pediatric oncology: a review. Med. Pediatr. Oncol. 39, 463–468 (2002).
   PubMedGoogle Scholar
• Leal Noval SR, Jara Lopez I. Do multiple blood transfusions predispose for a higher rate of nonblood-related infection complications? Clin. Microbiol. Infect. 8, 383–387 (2002).
   Google Scholar
• Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am. Surg. 68,566–572 (2002).
   Google Scholar
• Phillips J, Beam S, Brinker A et al. Retrospective analysis of mortalities associated with medication errors. Am. J. Health Syst. Pharm. 58,1835–1841 (2001).
   PubMed Web of Science ®Google Scholar
• Warner JO, Naspitz CK. Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr. Pulmonol. 25, 1–17 (1998).
   PubMed Web of Science ®Google Scholar
• Peat JK, van den Berg RH, Green WE Mellis CM, Leeder SR, Woolcock AJ. Changing prevalence of asthma in Australian children. Br. Med. J. 308, 1591–1596 (1994).
   PubMed Web of Science ®Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma: United States, 1980–1999. MMWR Surveill. Summ. 51(1), 1–13 (2002).
   Google Scholar
• Zbrozek AS, Cantor SB, Cardenas MP, Hill DP Jr. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am. J. Hosp. Pharm. 51,1555–1563 (1994).
   Google Scholar
• Holdsworth MT, Raisch DW, Winter SS, Chavez CM. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Support Care Cancer 6, 132–138 (1998).
   PubMed Web of Science ®Google Scholar
• Holdsworth MT, Adams VR, Raisch DW, Wood JG, Winter SS. Computerized system for outcomes-based antiemetic therapy in children. Ann. Pharmacother: 34, 1101–1108 (2000).
   Google Scholar
• Hart C, Chesson R. Children as consumers. Br. Med. J. 316,1600–1603 (1998).
   PubMed Web of Science ®Google Scholar